Recombinant Human LCN2 is produced by our mammalian expression system in human cells. The target protein is expressed with sequence (AA 21-198) of Human LCN2 fused with a polyhistidine tag at the C-terminus.
Reinheit
> 95 % as determined by reducing SDS-PAGE.
Sterilität
0.2 μm filtered
Endotoxin-Niveau
Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test
LCN2
Spezies: Human
Wirt: Escherichia coli (E. coli)
Recombinant
>95 % as determined by reducing SDS-PAGE.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Rekonstitution
It is not recommended to reconstitute to a concentration less than 100 μg/mL. Dissolve the lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Buffer
Supplied as a 0.2 μm filtered solution of PBS, 50 % glycerol, pH 7.4.
Handhabung
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Lagerung
-80 °C
Informationen zur Lagerung
Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
LCN2 is iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development. LCN2 binds iron through association with 2,5-dihydroxybenzoic acid (2,5-DHBA), a siderophore that shares structural similarities with bacterial enterobactin, and delivers or removes iron from the cell, depending on the context. LCN2 is involved in apoptosis due to interleukin-3 (IL3) deprivation: iron-loaded form increases intracellular iron concentration without promoting apoptosis, while iron-free form decreases intracellular iron levels, inducing expression of the proapoptotic protein BCL2L11/BIM, resulting in apoptosis. LCN2 is involved in innate immunity, possibly by sequestrating iron, leading to limit bacterial growth.